Navigation Links
Savient Pharmaceuticals to Hold First Quarter 2011 Financial Results
Date:4/21/2011

EAST BRUNSWICK, N.J., April 21, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that the company will release financial results for the first quarter 2011 prior to the open of the market on Thursday, May 5, 2011.

John H. Johnson, Chief Executive Officer, and David Gionco, Group Vice President and Chief Financial Officer, will host an investment community conference call beginning at 9:00 a.m. Eastern Time on May 5, 2011, to discuss these results and to answer questions.

To participate by telephone, please dial 888-357-3694 (Domestic) or 973-890-8276 (International). The conference identification number is 61789535. The live and archived webcast can be accessed on the investor relations section of the Savient website at www.savient.com. Please log on to Savient's website fifteen minutes prior to the start of the call to ensure adequate time for any downloads that may be necessary.

A telephone replay will be available from 12:00 p.m. Eastern Time on May 5, 2011, through 11:59 p.m. Eastern Time on May 23, 2011, by dialing 800-642-1687 (Domestic) or 706-645-9291 (International) and entering conference ID number 61789535.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the company website at www.savient.com.

SVNT-I


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Present at the ROTH 23rd Annual OC Growth Stock Conference
2. Savient Pharmaceuticals to Present at the 31st Annual Cowen & Co. Health Care Conference
3. Savient Pharmaceuticals Announces U.S. Launch of KRYSTEXXA™; Reports Fourth Quarter and Year-End 2010 Financial Results
4. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2010 Results Conference Call on Friday, February 25, 2011
5. Savient Closes Sale of $230 Million in Convertible Senior Notes
6. Savient Announces Proposed Offering of $125 Million in Convertible Senior Notes
7. Savient Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
8. Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer
9. Savient Pharmaceuticals Announces Search for CEO
10. Savient Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
11. Savient Pharmaceuticals Announces Expected Availability of KRYSTEXXA™ for Prescription and Reports Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Jan. 19, 2017 Report Details ... Alzheimer,s ... Leading Companies – our new study reveals trends, R&D ... and events affecting the Alzheimer,s disease therapeutics and diagnostics ... these key questions: - How is the Alzheimer,s disease ...
(Date:1/19/2017)... Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, Sympathomimetic-GABA Receptor ... market is expected to grow at a CAGR of 27.1% ... 38.7% in the second half of the forecast period. The market ... to 2027. The market is estimated at $1,058 million in 2016, ... ...
(Date:1/19/2017)... LONDON , January 19, 2017 ... Grothey ; European Oncology & Haematology, 2016;12(Suppl 2):3-8; ... ... http://photos.prnewswire.com/prnh/20151014/276718LOGO) Published recently in ... the peer-reviewed journal from touchONCOLOGY, an article by ...
Breaking Medicine Technology:
(Date:1/20/2017)... California (PRWEB) , ... January 20, 2017 , ... "TransFlare ... to use inside of Final Cut Pro X," said Christina Austin - CEO of ... the RED Dragon. Utilizing the Dragon Sensor,TransFlare 4K Mystique lens flare and light leak ...
(Date:1/20/2017)... ... ... Chocolate Biscuit”: a biographical account following a man who went on to support his country ... Ivey, born in Lynn Haven, Florida and at the age of 5, his family moved ... he joined the Navy and got married right out of boot camp. , He ...
(Date:1/20/2017)... ... ... a beautiful and enchanting tale that teaches children the true meaning of Christmas. “Journey to ... City, and a devoted woman of faith. , “Becoming a parent changes you. In ... my mind for years, but actually doing it might have been a while in coming ...
(Date:1/19/2017)... ... , ... Today, the Centers for Medicare & Medicaid Services (CMS) announced over ... (APMs) in 2017. Clinicians who participate in APMs are paid for the quality of ... Administration’s effort to build a system that delivers better care and one in which ...
(Date:1/19/2017)... ... ... weather here, many people will have to clear snow with snow blowers or shovels from ... they can be dangerous when used incorrectly. That’s why Amica Insurance is sharing ... snow blowers:, , When removing wet snow or debris from the ...
Breaking Medicine News(10 mins):